Stock AnalizArgenx SE ARGX
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2017 · data as of November 13, 2026
Argenx SE (ARGX) is a healthcare company listed in the US with a market value of about $59.6B. In the twelve months to September 30, 2026 it had revenue of $5.8B and net income of $1.9B, a net margin of 32.2%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (5/5); the weakest is value (0/5).
Key numbers: a P/E of 33.2, a price to free cash flow of 193.0, 5-year revenue growth of 131% a year, a 5-year average ROIC of -7%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 72% below the current price.
Score: 2.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
- Positive free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.8B | $4.2B | $2.3B | $1.3B | $445M | $539M | $65M | $94M | $21M | $44M | $16M |
| Net income | $1.9B | $1.3B | $833M | -$295M | -$710M | -$408M | -$608M | -$183M | -$76M | -$34M | — |
| Free cash flow | $309M | $679M | -$85M | -$421M | -$864M | -$610M | -$400M | $150M | — | — | — |
| EPS (diluted) | $28.88 | $20.82 | $13.42 | $-4.75 | $-11.43 | $-6.58 | $-9.80 | $-2.95 | $-1.23 | $-0.54 | — |
| Net margin | 32.2% | 30.4% | 37.0% | -23.3% | -159.4% | -75.7% | -937.4% | -194.7% | -355.2% | -77.1% | — |
| ROIC | — | 11.4% | -0.3% | -10.0% | -24.9% | -10.9% | -22.5% | -13.3% | -10.5% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 23 analysts is $1147.35, 20% above the current price; targets range from $861.00 to $1353.00; the consensus rating is “Buy”; expected EPS is $28.27 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Argenx’s P/E ratio?
About 33.2, based on the last twelve months of diluted earnings per share (forward P/E about 31.5).
Is Argenx stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 72% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Argenx pay a dividend?
Not currently.
Is Argenx a good stock to buy?
We do not give buy or sell advice. Argenx scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.